JULY 12, 2024 by Lori Solomon The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics’ Zoryve (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients (ages 6 years and older). Zoryve is a once-daily, steroid-free cream that the company says will be available at the end of July....
